Diabetologia:筛查工具可增加有关心血管结局的独立预后信息?

2018-04-10 MedSci MedSci原创

近日,国际杂志 《Diabetologia》上在线发表一项关于来自密歇根神经病变筛查的三个问题集增加有关心血管结局的独立预后信息的ALTITUDE试验的研究。自我管理的密歇根神经病变筛查工具(MNSI)用于诊断糖尿病周围神经病变。研究人员探讨了MNSI是否也可以提供有关死亡风险和心血管结局的信息。 在对阿利吉仑二型糖尿病使用心肾终点(ALTITUDE)试验的阿利克仑试验的事后分析中,研究人员

近日,国际杂志 《Diabetologia》上在线发表一项关于来自密歇根神经病变筛查的三个问题集增加有关心血管结局的独立预后信息的ALTITUDE试验的研究。自我管理的密歇根神经病变筛查工具(MNSI)用于诊断糖尿病周围神经病变。研究人员探讨了MNSI是否也可以提供有关死亡风险和心血管结局的信息。 在对阿利吉仑二型糖尿病使用心肾终点(ALTITUDE)试验的阿利克仑试验的事后分析中,研究人员将8463名患有2型糖尿病和慢性肾病(CKD)和/或心血管疾病(CVD)的参与者分为独立训练(n = 3252)和验证(n = 5211)组。在训练集中,研究人员确定了与心血管复合终点(心血管死亡,复苏心脏骤停,非致命性心肌梗死/中风,心力衰竭住院)独立相关的具体问题。然后,研究人员评估这些问题在验证集中的表现。 在训练集中,有三个问题(“你的腿麻了吗?”,“你脚上有过酸痛吗?”和“你的腿在走路时受伤了吗?”)与心血管复合结果显著相关。在验证集中,对关键协变量进行多变量校正后,相对于对所有问题无阳性反应,一项或多项阳性反应(n = 3079,59.1%)与心血管复合终点风险(HR 1.54 [95%

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655111, encodeId=697e1655111d1, content=<a href='/topic/show?id=aa1fe59284f' target=_blank style='color:#2F92EE;'>#筛查工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75928, encryptionId=aa1fe59284f, topicName=筛查工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ef224632617, createdName=jwf_2009, createdTime=Sat Jul 28 11:31:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638541, encodeId=5776163854104, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 04 05:31:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760627, encodeId=e2391e606277e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Dec 26 01:31:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269330, encodeId=03d912693304c, content=<a href='/topic/show?id=49d1518915a' target=_blank style='color:#2F92EE;'>#心血管结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51891, encryptionId=49d1518915a, topicName=心血管结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Apr 12 03:31:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655111, encodeId=697e1655111d1, content=<a href='/topic/show?id=aa1fe59284f' target=_blank style='color:#2F92EE;'>#筛查工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75928, encryptionId=aa1fe59284f, topicName=筛查工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ef224632617, createdName=jwf_2009, createdTime=Sat Jul 28 11:31:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638541, encodeId=5776163854104, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 04 05:31:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760627, encodeId=e2391e606277e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Dec 26 01:31:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269330, encodeId=03d912693304c, content=<a href='/topic/show?id=49d1518915a' target=_blank style='color:#2F92EE;'>#心血管结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51891, encryptionId=49d1518915a, topicName=心血管结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Apr 12 03:31:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1655111, encodeId=697e1655111d1, content=<a href='/topic/show?id=aa1fe59284f' target=_blank style='color:#2F92EE;'>#筛查工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75928, encryptionId=aa1fe59284f, topicName=筛查工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ef224632617, createdName=jwf_2009, createdTime=Sat Jul 28 11:31:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638541, encodeId=5776163854104, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 04 05:31:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760627, encodeId=e2391e606277e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Dec 26 01:31:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269330, encodeId=03d912693304c, content=<a href='/topic/show?id=49d1518915a' target=_blank style='color:#2F92EE;'>#心血管结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51891, encryptionId=49d1518915a, topicName=心血管结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Apr 12 03:31:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1655111, encodeId=697e1655111d1, content=<a href='/topic/show?id=aa1fe59284f' target=_blank style='color:#2F92EE;'>#筛查工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75928, encryptionId=aa1fe59284f, topicName=筛查工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ef224632617, createdName=jwf_2009, createdTime=Sat Jul 28 11:31:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638541, encodeId=5776163854104, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 04 05:31:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760627, encodeId=e2391e606277e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Dec 26 01:31:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269330, encodeId=03d912693304c, content=<a href='/topic/show?id=49d1518915a' target=_blank style='color:#2F92EE;'>#心血管结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51891, encryptionId=49d1518915a, topicName=心血管结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Apr 12 03:31:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]

相关资讯

Heart:高心血管风险的COPD患者:吸入性治疗影响心血管结局吗?

慢性阻塞性肺疾病(COPD)患者比普通人更容易患心血管疾病(CVD),COPD患者死亡中约1/3是由CVD引起的。尽管已有许多这方面的研究,但对于如何管理两种疾病共存的患者仍然是个难题。2017年10月,发表在《Heart》的一项由美国、英国和加拿大科学家进行的研究,考察了高CVD风险的COPD患者吸入β2激动剂/糖皮质激素的心血管结局。

Heart:勃起功能障碍治疗与心肌梗死后死亡或心血管结局有啥关系?

首次MI后ED治疗与降低的死亡率和心衰住院有关。只有用磷酸二酯酶-5抑制剂的男性患者才能降低风险,并且呈现剂量依赖性。

中华糖尿病杂志:从大型心血管结局研究分析糖尿病患者早期强化降糖策略

中国糖尿病患病率已高达9.7%,患病人数居世界首位。糖尿病及其相关并发症给社会带来了巨大的负担。2型糖尿病患者(T2DM)的心血管疾病风险是非糖尿病患者的2~4倍。尽管高血糖已被证实是心血管疾病的独立危险因素,但强化降糖治疗是否能够减少心血管并发症尚无定论。由于患者基线的差异、降糖目标及随访时间的不同,强化降糖治疗对心血管结局的影响不尽相同。本文从大型心血管结局研究入手,分析糖尿病患者早期强化降糖

Heart:动脉僵硬度对无高血压患者心血管结局的影响!

由此可见,高baPWV与更高的CAC评分以及未来心血管事件风险相关,尤其是冠状动脉疾病,即使在无高血压的患者中。

Diabetes Care:1型糖尿病患者体重增长过快对心血管结局的影响!

DCCT后第一个13年中,1型糖尿病患者采用INT治疗相比于CONV可以降低大血管事件,即使发生体重过度增加。在这之后,总心血管事件在Q4INT组显著增加,CONV组也有类似结果。需要更长的时间进行随访,以确定这种趋势是否持续,并导致更多的主要心血管事件。

Diabetes Care:二甲双胍或可调节DPP-4抑制剂对心血管结局的影响。

本研究的目的是探索普遍使用的二甲双胍对二肽基肽酶4抑制剂(DPP-4i)对心血管影响的潜在调节作用。